Five Prime Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference
01 déc. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Therapeutics Begins Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144
19 nov. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics to Present at the Jefferies Autumn 2015 Global Healthcare Conference
12 nov. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License and Collaboration Agreement With Bristol-Myers Squibb
11 nov. 2015 04h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics Announces Preliminary FPA008 Phase 1 Data in Rheumatoid Arthritis Patients Presented at the 2015 ACR Annual Meeting
10 nov. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics Immuno-Oncology Research Activities Featured in Poster Presentations at SITC 2015
05 nov. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics Reports Third Quarter 2015 Results and Provides Business Update
04 nov. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
Established license and collaboration agreement with Bristol-Myers Squibb for FPA008: $1.74 billion in upfront and milestone payments, double-digit royalties, and ability to continue development...
Five Prime Therapeutics to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 4
28 oct. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
15 oct. 2015 04h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing...
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Strategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing...